Participation in a clinical trial influences the future management of patients with gastro-oesophageal reflux disease in general practice

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 7, 2006, Pages 1117-1125

  Meineche Schmidt, V ^a   Hvenegaard, A ^b   Juhl, H H ^b  

^a Danish Institute for Health Services Research ^*  (Denmark)

^b Dansk Sundhedsinstitut   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EPIGASTRIC PAIN; FEMALE; GASTROESOPHAGEAL REFLUX; GENERAL PRACTICE; HUMAN; MALE; PATIENT ATTITUDE; PATIENT PARTICIPATION; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SYMPTOM; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FAMILY PRACTICE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 33748660060     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03046.x     Document Type: Article

References (13)

1. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54.
2. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomised, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34.
3. Meineche-Schmidt V, Juhl HH, Ostergaard JE, et al. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-esophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004; 19: 907-15.
4. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1998; 44: 1-16.
5. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: The efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2205; 21: 1299-312.
6. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 18: CD003245.
7. Chren MM, Landefeld CS. Physicians' behaviour and their interaction with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271: 684-9.
8. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001; 323: 1-7.
9. Armstrong D, Reyburn H, Jones R. A study of general practitioners' reason for changing their prescribing behaviour. BMJ 1996; 12: 949-52.
10. Schmock GT, Walton SM, Park HY, et al. Factors that influence prescribing decisions. Ann Phermacother 2004; 38: 557-62.
11. Taylor RJ, Bond CM. Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice. Br J Gen Pract 1991; 41: 244-8.
12. Webb S, Lloyd M. Prescribing and referral in general practice: a study of patients' expectations and doctors' action. Br J Gen Pract 1994; 44: 165-9.
13. Andersen M, Kragstrup J, Sondergaard J. How conducting a clinical trial affects physicians' guideline adherence and drug preference. JAMA 2006; 295: 2759-64.